Form 4 for XYL Xylem Inc.
Accepted 2025-03-06 00:00:00 ET · period of report 2025-03-04 · accession 0001562180-25-002143 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-06 | 2025-03-04 | XYL | Capers Dorothy Trefon | SVP, GC | S - Sale+OE | $127.26 | -12.0K | 8,015 | -60% | -$1.53M |
| DM | 2025-03-06 | 2025-03-04 | XYL | Capers Dorothy Trefon | SVP, GC | M - OptEx | $91.71 | +12.0K | 15.9K | +312% | +$1.10M |
| D | 2025-03-06 | 2025-03-05 | XYL | Capers Dorothy Trefon | SVP, GC | A - Grant | $129.67 | +1,398 | 9,413 | +17% | +$181.3K |
| DM | 2025-03-06 | 2025-03-04 | XYL | Capers Dorothy Trefon | SVP, GC | M - OptEx | $0.00 | -12.0K | 2,079 | -85% | $0 |
| D | 2025-03-06 | 2025-03-05 | XYL | Capers Dorothy Trefon | SVP, GC | A - Grant | $129.67 | +4,905 | 4,905 | New | +$636.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-04 | S | D | 12,026 | $127.26 | 8,015 | D | — | — | (F1) This price represents the weighted average price per share of common stock (each, a "Share") of Xylem Inc. (the "Issuer"). 12,026 Shares were executed at a range of prices from $125.25 to $125.35. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares sold at each price. |
| 2 | Common | Common Stock | 2025-03-04 | M | A | 4,158 | $101.09 | 20,041 | D | — | — | |
| 3 | Common | Common Stock | 2025-03-04 | M | A | 7,868 | $86.76 | 15,883 | D | — | — | |
| 4 | Common | Common Stock | 2025-03-05 | A | A | 1,398 | $129.67 | 9,413 | D | — | — | (F2) Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one third increments on March 5, 2026, March 5, 2027 and March 5, 2028. |
| 5 | Derivative | Non-Qualified Stock Option (Right to Buy) | 2025-03-04 | M | D | 7,868 | $0.00 | 0 | D | $86.76 · — to 2032-03-01 | 7,868 Common Stock | (F4) The March 1, 2022 option grant vested 2,623 options on March 1, 2023, 2,623 options on March 1, 2024, and 2,622 options on March 1, 2025. |
| 6 | Derivative | Non-Qualified Stock Option (Right to Buy) | 2025-03-04 | M | D | 4,158 | $0.00 | 2,079 | D | $101.09 · — to 2033-03-01 | 4,158 Common Stock | (F3) The March 1, 2023 option grant vested 2,079 options on March 1, 2024, 2,079 options on March 1, 2025, and will vest 2,079 options on March 1, 2026. |
| 7 | Derivative | Non-Qualified Stock Options (Right to buy) | 2025-03-05 | A | A | 4,905 | $129.67 | 4,905 | D | $129.67 · — to 2035-03-05 | 4,905 Common Stock | (F5) Reflects an award of non-qualified stock options pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one-third increments on March 5, 2026, March 5, 2027 and March 5, 2028. |